Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 thr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature microbiology 2020-10, Vol.5 (10), p.1185-1191
Hauptverfasser:	Lee, Wen Shi, Wheatley, Adam K., Kent, Stephen J., DeKosky, Brandon J.
Format:	Artikel
Sprache:	eng
Schlagworte:	13/1 631/250/255 631/61/24 Animals Antibodies Antibodies, Monoclonal - administration & dosage Antibodies, Neutralizing - administration & dosage Antibodies, Viral - administration & dosage Antibodies, Viral - immunology Antibody-Dependent Enhancement - immunology Betacoronavirus - immunology Biomedical and Life Sciences Clinical trials Coronavirus Infections - drug therapy Coronavirus Infections - immunology Coronavirus Infections - prevention & control Coronavirus Infections - therapy Coronaviruses COVID-19 COVID-19 Drug Treatment COVID-19 Serotherapy COVID-19 Vaccines Dengue fever Humans Immunization, Passive - adverse effects In Vitro Techniques Infectious Diseases Life Sciences Medical Microbiology Microbiology Models, Immunological Pandemics - prevention & control Parasitology Perspective Pneumonia, Viral - immunology Pneumonia, Viral - prevention & control Pneumonia, Viral - therapy Respiratory syncytial virus Respiratory Tract Diseases - etiology Respiratory Tract Diseases - immunology Risk Factors Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccines Viral Vaccines - adverse effects Viral Vaccines - immunology Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!